Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 28, 2013; 19(32): 5326-5333
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5326
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5326
Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro
Feng-Rui Yang, Bu-Wu Fang, Jian-Shi Lou, Department of Pharmacology, Tianjin Medical University, Tianjin 300070, China
Author contributions: Fang BW and Lou JS designed the research; Yang FR performed the research and wrote the paper.
Supported by The Major Project of Applied Basic Research Plan of the Scientific and Technological Department of Tianjin, China, No. 06YFJZJC 02900
Correspondence to: Jian-Shi Lou, Professor, Department of Pharmacology, Tianjin Medical University, No. 22, Qixiangtai Road, Heping District, Tianjin 300070, China. jianshilou@126.com
Telephone: +86-22-83336686 Fax: +86-22-83336686
Received: May 14, 2013
Revised: July 2, 2013
Accepted: July 17, 2013
Published online: August 28, 2013
Processing time: 105 Days and 7.4 Hours
Revised: July 2, 2013
Accepted: July 17, 2013
Published online: August 28, 2013
Processing time: 105 Days and 7.4 Hours
Core Tip
Core tip: Fufang Biejia Ruangan Pill (FFBJRGP) is the first anti-fibrosis drug approved by the China State Food and Drug Administration. It has been demonstrated that FFBJRGP has a better efficacy of anti-fibrosis. However, the underlying therapeutic mechanisms of FFBJRGP in hepatic fibrosis are still unclear. In our study, FFBJRGP showed a strong ameliorative effect in hepatic fibrosis in vivo and in vitro. It reduced production and deposition of collagen in liver tissues. FFBJRGP inhibited expression of transforming growth factor (TGF-β1) and Smad3, which implied that inhibition of TGF-β/Smad-mediated fibrogenesis may be a central mechanism by which FFBJRGP protects against liver injury.